|
![]() |
|
|
Chloroquine
drug data and news
Chloroquine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Chloroquine | ||
| Brand Names/Synonyms | 3377 RP; 3377 RP opalate; Amokin; Aralen; Aralen HCl; Arechin; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chloroquina; Chloroquine; Chloroquine Phosphate; Chloroquinium; Chlorquin; Cidanchin; Clorochina; Cocartrit; Delagil; Dichinalex; Elestol; Gontochin; Heliopar; Hydroxychloroquine Sulfate; Imagon; Iroquine; Klorokin; Lapaquin; Malaquin; Malaren; Malarex; Mesylith; Neochin; Nivachine; Nivaquine; Nivaquine B; Nivaquine [as sulfate]; Pfizerquine; Plaquenil; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; Resochen; Resochin; Resoquina; Resoquine; Reumachlor; Reumaquin; Roquine; SN 6718; SN 7618; Sanoquin; Silbesan; Siragan; Solprina; Sopaquin; Tanakan; Tresochin; Trochin; W 7618; WIN 244; Chloroquine (VAN) | ||
| Indication | For the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Chloroquine is the prototype anti malarial drug, most widely used to treat all types of malaria except for disease caused by chloroquine resistant Plasmodium falciparum. It is highly effective against erythrocytic forms of Plasmodium vivax, Plasmodium ovale and Plasmodium malariae, sensitive strains of Plasmodium falciparum and gametocytes of Plasmodium vivax. Being alkaline, the drug reaches high concentration within the food vacuoles of the parasite and raises its pH. It is found to induce rapid clumping of the pigment. Chloroquine inhibits the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. It may also interfere with the biosynthesis of nucleic acids. | ||
| Mechanism Of Action | The mechanism of plasmodicidal action of chloroquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. | ||
| Chloroquine News (When available) |
Adding Chloroquine to Conventional Chemotherapy and Radiotherapy ... 06 Mar 2006 Indians isolate anti-malarial compounds 06 Mar 2006 Killer Number One: The fight against malaria, IRIN-In-Depth Mar 5, 2006 New malaria treatment out Mar 3, 2006 The New Malaria Drug Policy Feb 28, 2006 Drug Watch Mar 2, 2006 Pending issues on policy change Mar 1, 2006 Recognition of herbal medicine not enough Feb 27, 2006 Health advocates: Don't stop at sunscreen Mar 2, 2006 New Malaria Drug Free Feb 22, 2006 Add new comment Feb 19, 2006 For Methotrexate-Refractory RA, Try Again Feb 24, 2006 Malaria awareness drive must in Koraput Feb 21, 2006 Feb. 27 - MIP Seminar: ‘Drug Discovery for Malaria, a Novel ... Feb 22, 2006 Multi-component drug delivery system: An emerging trend Feb 8, 2006 Vaccine Development Costs Dm500 Feb 21, 2006 Have a healthy holiday Feb 19, 2006 Now, head for forests without malaria scare Feb 19, 2006 Old drugs find novel anti-cancer applications Feb 14, 2006 Zambia: Cause for optimism in malaria battle Feb 2, 2006 first line of malaria treatment Feb 7, 2006 Health bureau states medical claim limits for Taiwanese tourists Feb 3, 2006 Plaquenil for Alopecia Areata, Alopecia Totalis Feb 18, 2006 Fansidar to be replaced by Dec Feb 3, 2006 Manjasi took bullying to an ugly level Feb 18, 2006 Health Ministry Imports Stronger Malaria Drug Feb 3, 2006 Prices of 112 formulations reduced Feb 1, 2006 NPPA Fixes/Revises Prices Of Bulk Drugs And Formulations Feb 1, 2006 NPPA reduces prices of 112 formulations Feb 1, 2006 Rwanda :Malaria Infection Linked to Rampant Poverty Feb 2, 2006 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antirheumatic Agents; Antimalarials; Amebicides; ATC:P01BA01; ATC:P01BA02 | ||
| Absorption | Completely absorbed from gastrointestinal tract | ||
| Interactions | Interactions for Chloroquine: Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level. Concomitant use of cimetidine should be avoided. Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. An interval of at least two hours between intake of this agent and chloroquine should be observed. Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported. Therefore, close monitoring of serum cyclosporin level is recommended and, if necessary, chloroquine should be discontinued. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N'-(7-chloroquinolin-4-yl)-N,N-diethyl-pentane-1,4-diamine | ||
| Chemical Formula | C18H26ClN3 | ||
| Molecular Weight | 319.872 g/mol | ||
| Smiles String | CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl | ||
| Melting Point | 289 °C | ||
| Water Solubility | 10.6 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 4.474 | ||
| Isoelectric Point | 10.1 | ||
| Biotransformation | Hepatic (partially) | ||
| Half Life | 1-2 months | ||
| Protein Binding [%] | ~55% of the drug in the plasma is bound to nondiffusible plasma constituents | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Chloroquine.html http://www.rxlist.com/cgi/generic2/hquine2.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00468 | ||
| CAS Registry Number | 54-05-7 | ||
| KEGG Compound ID | C07625 | ||
| PubChem ID | SID:9827 | ||
| PharmGKB ID | PA448948 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 21261 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |